Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588.
le Coutre P, Kreuzer KA, Pursche S, Bonin Mv, Leopold T, Baskaynak G, Dörken B, Ehninger G, Ottmann O, Jenke A, Bornhäuser M, Schleyer E. le Coutre P, et al. Among authors: schleyer e. Cancer Chemother Pharmacol. 2004 Apr;53(4):313-23. doi: 10.1007/s00280-003-0741-6. Epub 2003 Dec 5. Cancer Chemother Pharmacol. 2004. PMID: 14658008
Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations.
Schleyer E, Pursche S, Köhne CH, Schuler U, Renner U, Gschaidmeier H, Freiberg-Richter J, Leopold T, Jenke A, Bonin M, Bergemann T, le Coutre P, Gruner M, Bornhäuser M, Ottmann OG, Ehninger G. Schleyer E, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Jan 5;799(1):23-36. doi: 10.1016/j.jchromb.2003.10.025. J Chromatogr B Analyt Technol Biomed Life Sci. 2004. PMID: 14659433
Increased myelotoxicity of idarubicin: is there a pharmacological basis? Results of a pharmacokinetic and an in vitro cytotoxicity study.
Kroschinsky F, Schleyer E, Renner U, Schimming C, Schimmelpfennig C, Bornhäuser M, Illmer T, Trümper L, Ehninger G, Schaich M. Kroschinsky F, et al. Among authors: schleyer e. Cancer Chemother Pharmacol. 2004 Jan;53(1):61-7. doi: 10.1007/s00280-003-0700-2. Epub 2003 Sep 3. Cancer Chemother Pharmacol. 2004. PMID: 12955471 Clinical Trial.
CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid.
Bornhauser M, Jenke A, Freiberg-Richter J, Radke J, Schuler US, Mohr B, Ehninger G, Schleyer E. Bornhauser M, et al. Among authors: schleyer e. Ann Hematol. 2004 Jun;83(6):401-2. doi: 10.1007/s00277-003-0829-4. Epub 2003 Dec 12. Ann Hematol. 2004. PMID: 14673623
Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib.
Bornhäuser M, Pursche S, Bonin M, Freiberg-Richter J, Jenke A, Illmer T, Ehninger G, Schleyer E. Bornhäuser M, et al. Among authors: schleyer e. J Clin Oncol. 2005 Jun 1;23(16):3855-6; author reply 3857-8. doi: 10.1200/JCO.2005.05.246. J Clin Oncol. 2005. PMID: 15923584 No abstract available.
Pharmacology and pharmacokinetics of imatinib in pediatric patients.
Suttorp M, Bornhäuser M, Metzler M, Millot F, Schleyer E. Suttorp M, et al. Among authors: schleyer e. Expert Rev Clin Pharmacol. 2018 Mar;11(3):219-231. doi: 10.1080/17512433.2018.1398644. Epub 2017 Nov 6. Expert Rev Clin Pharmacol. 2018. PMID: 29076384 Review.
Imatinib mesylate selectively influences the cellular metabolism of cytarabine in BCR/ABL negative leukemia cell lines and normal CD34+ progenitor cells.
Bornhäuser M, Illmer T, Le Coutre P, Pursche J, von Bonin M, Freiberg-Richter J, Schaich M, Platzbecker U, Thiede C, Ottmann OG, Köhne Ch, Braess J, Ehninger G, Schleyer E. Bornhäuser M, et al. Among authors: schleyer e. Ann Hematol. 2004;83 Suppl 1:S61-4. doi: 10.1007/s00277-004-0850-2. Ann Hematol. 2004. PMID: 15124675 Review.
85 results